Picture of Hansa Biopharma AB logo

HNSA Hansa Biopharma AB Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Hansa Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-360-423-548-611-832
Depreciation
Non-Cash Items7.1543.856.471.418
Purchased R&D
Other Non-Cash Items
Changes in Working Capital10.381.12.122538.3
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-335-290-481-503-756
Capital Expenditures-3.43-0.294-2.4-3.33-0.284
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items89.218302330
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities85.8183-2.4229-0.284
Financing Cash Flow Items-7.65-0.001
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-8.881,066-4.861,118-7.54
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-258958-488845-764